Related Experiment Video

Updated: Mar 22, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy

Mohammed Jarrar1, Shalini Behl1, Ganiraju Manyam2

  • 1College of Biotechnology, University of Modern Sciences, Dubai, United Arab Emirates.

Molecular Biology Reports
|April 14, 2016
PubMed

Insights

Genetic variations in cytochrome P450 enzymes significantly affect clopidogrel effectiveness for acute coronary syndrome. Understanding these CYP polymorphisms is crucial for optimizing antiplatelet therapy and patient outcomes.

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Drug Metabolism

Background:

  • Clopidogrel and aspirin are key dual antiplatelet therapies for acute coronary syndrome (ACS).
  • Clopidogrel's efficacy is modulated by hepatic cytochrome P450 (CYP) enzymes, particularly CYP2C19 and CYP3A4/5.
  • Genetic variations (polymorphisms) in these CYPs influence clopidogrel metabolism and clinical outcomes.

Purpose of the Study:

  • To investigate the impact of CYP enzyme variants on clopidogrel efficacy in ACS patients.
  • To explore potential interactions between clopidogrel, proton pump inhibitors (PPIs), and CYP polymorphisms.
  • To review the influence of CYP allelic variants on cardiovascular events and stent thrombosis.

Main Methods:

  • Literature review and analysis of recent studies.
  • Discussion of the role of CYP2C19 and CYP3A4/5 in clopidogrel metabolism.
  • Examination of clinical trial data regarding clopidogrel and PPI combinations.

Main Results:

  • Inconclusive clinical trial results on clopidogrel and PPI combination therapy may stem from CYP genetic variations.
  • CYP2C19 and CYP3A4/5 polymorphisms can significantly alter clopidogrel's therapeutic effectiveness.
  • Allelic variants may impact cardiovascular event rates and stent thrombosis in patients treated with clopidogrel.

Conclusions:

  • CYP enzyme genetic variations are critical determinants of clopidogrel response in ACS.
  • Further research is needed to elucidate the precise impact of specific CYP polymorphisms on clopidogrel therapy.
  • Understanding ethnic and demographic variations in CYP prevalence is essential for personalized antiplatelet treatment strategies.

Keywords:
Acute coronary syndromeBiodrugsCYP2C19CYP3A4Cardiovascular eventsClopidogrelClopidogrel metabolismProton pump inhibitors

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.5K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.4K

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
117
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
106
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
104
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
161
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
105